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Bladder cancer (BC), a tumour with high heterogeneity, has a high
incidence and recurrence rate, with frequent alterations in several
signalling pathways. The mammalian target of rapamycin (mTOR)
pathway is altered in 72% of BC cases. Interestingly, the role of SIRT1
in tumorigenesis has been a matter of controversy since it can act both
as a tumour promoter or tumour suppressor, suggesting that it has
different roles according with the characteristics of the tumour. In
recent studies, mitochondrial functions, metabolic pathways and
signalling proteins have been related to both SIRT1 and mTOR
pathways. Herein, we hypothesize that SIRT1 has a role in BC
progression and that it interacts with mTOR pathway, modulating
bioenergetics and metabolic features.
Mitochondrial potential was almost nullified after exposure to the combined treatment with both inhibitors in BC cells of both stages and
mitochondrial proton leak was slightly increased in TCCSUP cell line respirometry.
SIRT1 activation upregulated GLUT3 and MCT1 in HT-1376 cells
without alteration on metabolites levels. mTOR inhibition alone also
upregulated GLUT3, MCT1 and MCT4 expression in HT-1376 cells and
increased MCT4 in TCCSUP cells, but with no direct action on
metabolites levels.
The combined treatment with SIRT1 and mTOR inhibitors significantly
decreased lactate production in TCCSUP cells and alanine was





Our data showed that SIRT1 alteration have differential effects on BC cells of both grades, suggesting a possible therapeutic target for BC 
progression. These studies highlight the need to preselect patients based on metabolic cancer phenotype, since the cells’ behaviour from different 
stages diverse in metabolic genes, metabolites involved and mitochondrial function. In the context of personalized medicine, these differences in 
signalling pathways are essential for a specific diagnosis and therapy of each particular tumour. Overall, our data suggest that SIRT1 and mTOR are 
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Effect of YK-3-237, EX-527 and rapamycin, aswell as the combined treatment (EX-527 with rapamycin) in mRNA
expression of GLUT3 and MCT1 genes of bladder cancer cells HT-1376 and mRNA expression of MCT4 gene of both cell
lines. mRNA expression results are presented in arbitrary units. Results are presented as mean±SEM (n=6). *p<0.05,
relatively to control group. **p<0.01, relatively to control group. ***p<0.001, relatively to control group.
Effect of YK-3-237, EX-527 and rapamycin, aswell as the combined treatment (EX-527 with rapamycin) in alanine and
lactate production TCCSUP cells. Results are presented as mean±SEM (n=6). *p<0.05, relatively to control group.
**p<0.01, relatively to control group.
Effect of YK-3-237, EX-527 and rapamycin, aswell as the combined treatments in mitochondrial potential of HT-1376 and
TCCSUP cells. Results were obtained by JC-1 assay and are presented as mean±SEM (n=6). **p<0.01, relatively to
control group. ****p<0.0001, relatively to control group. a – significant result relative to EX-527+rapamycin group. b –
significant result relative to YK-3-237+rapamycin group.
Effect of YK-3-237, EX-527 and rapamycin, aswell as the combined treatment (EX-527 with rapamycin) in oxygen
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